Bayer AG (FRA:BAYA) Valuation Rank


FRA:BAYA Bayer AG FRA:BAYA
62 GF Score
Price €12.30
GF Value €6.80
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Bayer AG Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Bayer AG Valuation Rank Related Terms

FRA:BAYA
62GF Score
Bayer AG FRA:BAYA
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bayer AG (FRA:BAYA) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of €12.30 is trading 80.9% above its estimated GF Value™ of €6.80. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for FRA:BAYA:

  • Valuation Rank:
  • GF Value™: €6.80 vs. price of €12.30 (80.9% above fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the FRA:BAYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
62GF Score

Get the complete analysis for FRA:BAYA

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.30
Price
€6.80
GF Value